Jove
Visualize
Contact Us

Related Concept Videos

Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
Issues And Trends In Healthcare Delivery System01:29

Issues And Trends In Healthcare Delivery System

The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the appropriate...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Initial validation of a pediatric cataplexy survey for children and adolescents with narcolepsy type 1.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine·2026
Same author

Development of the pediatric narcolepsy patient-reported outcomes scale (PN-PROs).

Frontiers in sleep·2025
Same author

Barriers to Accessing Opioid Treatment in Rural Queensland: Perspectives From Consumers and Clinicians.

Drug and alcohol review·2025
Same author

Investigating the relationship between gut microbiota and electrocortical signatures of feedback processing: an ERP study.

Psychopharmacology·2025
Same author

Interoception, personality, and internet use: Preliminary insights into their association.

PloS one·2025
Same author

"Honoring Beautiful Connections": LGBTQA+ Perspectives on Providing Safe and Inclusive Psychedelic-Assisted Therapy.

Journal of homosexuality·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

International perspectives on AI-driven pharmaceutical IP challenges.

Grace Y Wang1, Jian-Ming Hao2, Joe G Chen2

  • 1West Windsor High School-North, West Windsor, NJ, United States.

Frontiers in Digital Health
|July 13, 2026
PubMed
Summary

Artificial Intelligence (AI) is revolutionizing drug design and personalized medicine. However, AI inventorship challenges impact pharmaceutical intellectual property (IP) protection, particularly under US law.

Keywords:
artificial intelligencecopyrightdrug discoveryintellectual propertyinternational perspectiveinventorshippatent lawpersonalized medicine

Related Experiment Videos

Area of Science:

  • Pharmaceutical Science
  • Intellectual Property Law
  • Artificial Intelligence

Background:

  • Artificial Intelligence (AI) significantly impacts pharmaceutical development, from optimizing patient care to accelerating drug discovery.
  • The integration of AI into pharmaceuticals introduces complex challenges for existing intellectual property (IP) frameworks, especially concerning inventorship.
  • Patent protection for AI-driven innovations is a critical concern for the pharmaceutical sector.

Purpose of the Study:

  • To review AI-driven innovations in personalized medicine and drug design.
  • To analyze inventorship issues affecting pharmaceutical patent protection.
  • To examine legal developments and comparative approaches to AI inventorship in the US, Germany, and China.

Main Methods:

  • Literature review of AI applications in pharmaceuticals.
  • Analysis of US legal precedents, including Thaler v. Perlmutter.
  • Comparative legal analysis of inventorship laws in Germany and China.

Main Results:

  • The US Supreme Court's denial of certiorari in Thaler v. Perlmutter definitively resolved AI inventorship under US law.
  • Comparative analysis reveals differing international approaches to AI inventorship.
  • Specific, targeted lessons for stakeholders were identified.

Conclusions:

  • Navigating the intersection of AI and pharmaceutical IP requires understanding evolving legal landscapes.
  • The US legal framework now clarifies that AI cannot be an inventor.
  • Stakeholders can adapt by focusing on specific lessons rather than broad reforms to manage AI-related IP challenges.